MS
IOVA icon

Murray Stahl’s Iovance Biotherapeutics IOVA Stock Holding History

Murray Stahl’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-28,076
Closed -$688K – 488
2019
Q2 		$688K Sell
28,076
-13,461
-32% -$203K 0.02% 224
2019
Q1 		$395K Buy
+41,537
New +$403K 0.01% 283

Other funds holding IOVA

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Murray Stahl's IOVA Position: Q3 2019 in Review

Murray Stahl sold out of Iovance Biotherapeutics (IOVA) in Q3 2019, closing a stake of 28,076 shares — an estimated $688K sold.

Murray Stahl first reported a position in IOVA in Q1 2019 and held it in 2 quarters. The position peaked at $688K in Q2 2019. 173 funds tracked by Wall St. Rank hold IOVA as of Q3 2019.

  • Murray Stahl reported no remaining Iovance Biotherapeutics position as of Q3 2019 after selling out during the quarter.
  • Murray Stahl sold 28,076 Iovance Biotherapeutics shares in Q3 2019, an estimated $688K.
  • Murray Stahl first reported a position in Iovance Biotherapeutics in Q1 2019 and held it in 2 quarters.
  • Murray Stahl's Iovance Biotherapeutics position peaked at $688K in Q2 2019.
  • 173 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q3 2019.

Based on Horizon Kinetics Asset Management's 13F filing for Q3 2019, filed 14 Nov 2019.